So TMC435 will be tested with the two leading HCV nukes—GILD’s GS7977 and BMY’s BMS-986094 (f/k/a INX-189)—and also with BMY’s NS5A inhibitor, daclatasvir. For Medivir, the news could hardly be better.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”